LENZ THERAPEUTICS ($LENZ) posted quarterly earnings results for Q1 2026 on Monday, May 11th. The company reported earnings of -$1.32 per share, missing estimates of -$1.09 by $0.23. The company also reported revenue of $1,900,000, beating estimates of $1,794,037 by $105,963.
Stock price change since market close: -4.55%
You can see Quiver Quantitative's $LENZ stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
LENZ THERAPEUTICS Insider Trading Activity
LENZ THERAPEUTICS insiders have traded $LENZ stock on the open market 5 times in the past 6 months. Of those trades, 3 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $LENZ stock by insiders over the last 6 months:
- SHAWN OLSSON (Chief Commercial Officer) has made 0 purchases and 2 sales selling 10,000 shares for an estimated $261,022.
- EVERT B. SCHIMMELPENNINK (President, CEO and Secretary) purchased 28,089 shares for an estimated $251,410
- DANIEL R. CHEVALLARD (Chief Financial Officer) purchased 7,500 shares for an estimated $64,275
- JEFFREY P. GEORGE purchased 5,592 shares for an estimated $49,890
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
LENZ THERAPEUTICS Hedge Fund Activity
We have seen 104 institutional investors add shares of LENZ THERAPEUTICS stock to their portfolio, and 86 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 3,615,405 shares (+4140.7%) to their portfolio in Q4 2025, for an estimated $57,846,480
- UBS GROUP AG removed 1,414,749 shares (-90.0%) from their portfolio in Q1 2026, for an estimated $12,944,953
- PARADIGM BIOCAPITAL ADVISORS LP removed 1,073,461 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $17,175,376
- RTW INVESTMENTS, LP removed 863,389 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $13,814,224
- PRICE T ROWE ASSOCIATES INC /MD/ added 772,411 shares (+307.6%) to their portfolio in Q4 2025, for an estimated $12,358,576
- FIRST LIGHT ASSET MANAGEMENT, LLC removed 693,044 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $11,088,704
- ABERDEEN GROUP PLC added 666,729 shares (+136.2%) to their portfolio in Q1 2026, for an estimated $6,100,570
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
LENZ THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $LENZ recently. We have seen 3 analysts offer price targets for $LENZ in the last 6 months, with a median target of $29.0.
Here are some recent targets:
- Matthew Caufield from HC Wainwright & Co. set a target price of $48.0 on 04/21/2026
- Yigal Nochomovitz from Citigroup set a target price of $26.0 on 03/26/2026
- Jason Gerberry from B of A Securities set a target price of $29.0 on 03/25/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
